American Diabetes Association 70th Scientific Sessions
Jun 28, 2010
12:00 PM - 2:00 PM
Improvements in Dyslipidemia and Other Cardiometabolic Disease Risk
Factors with Low-Dose, Controlled-Release Phentermine / Topiramate
(PHEN/TPM) # 1083-P
1:00PM - 2:00PM Changes in Insulin Sensitivity in Overweight/Obese Patients Treated with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) # 1842-P
1:00 PM - 2:00 PM Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) and Markers of Type 2 Diabetes Mellitus (T2DM) # 1846-P
1:00 PM - 2:00 PM Magnitude of Weight Loss Experienced with a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) May Drive Degree of Cardiometabolic Benefit # 1847-P
5:45 PM - 6:00 PM Presented During Session: Obesity--Human Pathophysiology and Treatment A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes # 0382-OR
1:00PM - 2:00PM Changes in Insulin Sensitivity in Overweight/Obese Patients Treated with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) # 1842-P
1:00 PM - 2:00 PM Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) and Markers of Type 2 Diabetes Mellitus (T2DM) # 1846-P
1:00 PM - 2:00 PM Magnitude of Weight Loss Experienced with a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) May Drive Degree of Cardiometabolic Benefit # 1847-P
5:45 PM - 6:00 PM Presented During Session: Obesity--Human Pathophysiology and Treatment A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes # 0382-OR
Location
Orange County Convention Center